PI3K/Akt/mTOR signalling pathway activation in patients with ER‑positive, metachronous, contralateral breast cancer treated with hormone therapyHirofumi Kanaizumi(Kindai University), Yoshifumi Komoike(Kindai University Hospital)Oncology LettersNovember 26, 201810.3892/ol.2018.9759Cited by 16SaveCiteExport RISWatch citationsRelated PapersPI3K/Akt/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapy|European Journal of Cancer|2018|13